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Abstract
Background: The frequently occurring 185delAG mutation occurs in the amino-terminal zinc
RING domain of the breast and ovarian cancer susceptibility gene, BRCA1. We sought to
determine differential cell viability and apoptotic response of human ovarian surface epithelial cells
with and without the 185delAG mutation.
Results: BRCA1wt and BRCA1+ cells were treated with staurosporine. Cell proliferation assays
showed BRCA1wt cells grew to a greater extent compared to BRCA1+ cells. Trypan blue
exclusion assays confirmed this observation. Western immunoblot analysis revealed that caspase 3
levels were higher after staurosporine treatment in BRCA1+ cells than in wild type cells, while full
length DNA Fragmentation Factor 45 levels were lower in BRCA1+ cells. While there was no
significant difference in levels of excision repair cross complementing protein1 (ERCC1) with
BRCA1 status, BRCA1+ cells demonstrated cleavage of polyribose ADP polymerase (PARP) before
wild type cells.
Conclusions: Disruption of the BRCA1 RING domain caused altered cell viability and caspase-
dependent apoptotic response after chemotoxic stress.
Background
The breast and ovarian cancer susceptibility gene, BRCA1,
is located at 17q21, and encodes a 1863 amino acid pro-
tein. Mutations in this gene account for 60% of hereditary
ovarian cancers [1]. Loss of heterozygosity in this gene oc-
curs in 30–70% of sporadic ovarian carcinomas [2]. Spe-
cies homology studies have shown that while the entire
22 exon gene is poorly conserved, the terminal ends main-
tain over an 80% homology between rat, human and
mouse [3]. BRCA1 has long been known to function in
DNA repair. Studies have shown BRCA1 is upregulated in
cells treated by DNA damaging agents such as cisplatinum
[4]. BRCA1 has been shown to interact with DNA repair
proteins such as Rad50 and Rad51, the tumor suppressor
genes RB and BRCA2, transcriptional factors (RNA pol II,
histone deacetylase complex, ctIP) as well as influence nu-
merous cyclins and cyclin dependent kinases contributing
to cell cycle regulation [5–12]. More recently, BRCA1 has
been shown to influence apoptosis in a p53 independent
manner [13]. This apoptotic response involved the c-jun
kinase (JNK) pathway, though the details of this mecha-
nism remain unclear [14].
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The highly acidic carboxy-terminal (BRCT) region of
BRCA1 has been suggested to play a role in transactivation
[11]. BRCT interacts with BRCA2, Rad51, other tumor
suppressing elements, as well as numerous transcription
factors, such as RNA helicase A and STAT1 [15,16]. Re-
cently, it has been discovered that truncation of this re-
gion resulted in suppression of apoptosis following pro-
apoptotic stimuli [17]. Further, these studies also suggest-
ed that the BRCT region facilitates apoptotic functions
within the caspase pathway.
The amino terminal (BRNT) of BRCA1 contains a highly
conserved zinc binding or RING finger domain also in-
volved in multiple functions within the cell. Molecular
modeling has shown that this domain contains two zinc
finger-like motifs connected through linking C3HC4 re-
gions [18]. Naturally occurring splice variants of the gene
suggest at least two transcription initiation points above
and below the coding region for the RING domain [19].
Truncation studies have shown that the RING domain
may function in direct protein binding of ER-α , ATF1, and
BARD1, a ubiquitin ligase [20–22]. While zinc RING do-
mains are common motifs in several protein families such
as oncoproteins and regulatory proteins, the actual func-
tion of the domain differs among these proteins. For ex-
ample, inhibitors of apoptosis proteins, (IAPs), contain
one to three tandem baculovirus inverted repeat (BIR) do-
mains as well as a carboxy terminal RING domain. Previ-
ous studies have shown this RING domain essential in the
anti-apoptotic function of some IAPs [23].
The most common mode a cell uses to undergo apoptosis
is the cysteine-aspartate specific protease (caspase) path-
way. This proteolytic cascade may be triggered by a wide
variety of stimuli and employs numerous initiation routes
within the cell. While there is extensive crosstalk between
the caspases, the two most common initiator pathways
are the Fas/Fas ligand pathway, involving caspase 8 and
caspase 10, and the mitochondrial pathway, triggering
caspase 9 [24,25]. Caspase 3, a pivotal downstream pro-
tease, functions in virtually every caspase pathway and
serves as an executioner in the cells by cleavage of down-
stream targets which lead to irreversible chromosomal
degradation. Perhaps the most prominent caspase 3 sub-
strate is DNA Fragmentation Factor 45 (DFF45), an inhib-
itor of caspase-activated DNase [26]. Following caspase 3-
mediated cleavage, DFF45 releases DFF40, the DNase re-
sponsible for DNA fragmentation into the characteristic
apoptotic DNA ladder. Caspase 3 also deactivates vital
DNA repair enzymes such as poly ribose ADP polymerase
(PARP) [27]. Cleavage of PARP has been regarded as a
hallmark of caspase-dependent apoptosis [28].
No study to date has explored the possible involvement of
the BRCA1 amino-terminal RING domain in caspase-me-
diated apoptosis. Therefore, ovarian surface epithelial cell
lines with and without the 185delAG BRCA1 mutation
were used to ascertain whether the RING domain of the
amino-terminal affected apoptosis. This mutation, com-
mon among families with hereditary ovarian cancer, is a
frameshift mutation occurring at the beginning of the
C3HC4 region of exon 2 that essentially interrupts RING
domain function [19,29,30]. The results showed that dis-
ruption of the BRCA1 amino-terminal RING domain al-
tered caspase 3 activation and subsequent DFF45 and
PARP cleavage, resulting in accelerated STS-induced apop-
tosis.
Results
Loss of BRCA1 expression resulted in increased cell death 
when exposed to 1 µM staurosporine treatment
SV-40 large T antigen transfected ovarian surface epithelial
cell lines from women with and without an amino-termi-
nal BRCA1 mutation were employed to ascertain the func-
tion of the amino-terminal RING domain in apoptosis
[31]. To confirm BRCA1 status in these cell lines, whole
cell lysates were western blotted using a monoclonal anti-
BRCA1 antibody against the amino-terminal (Figure 1).
Using the MCF7 breast carcinoma cell line as a positive
control, MCC5 cells expressed the full length 216 kDa
BRCA1 protein and were confirmed BRCA1wt. In con-
trast, the HIO3261-77 cells were found to have signifi-
cantly reduced levels of full length BRCA1 than the wild
type cell line, confirming the mutated amino-terminal
BRCA1 (BRCA1+) in these cells. Due to the high molecu-
lar weight of BRCA1, actin could not be used as a loading
control. Thus, the membranes were stained with 7% Ami-
do black with the protein front used as a loading control.
Having confirmed the BRCA1 status of these cell lines, cell
viability was then assayed under cytotoxic stress. Cells
were treated with 1 µM STS for 3 h and subjected to MTS
Figure 1
BRCA1 expression is decreased in the HIO3261-77 cells.
One hundred thousand cells were electrophoresed in a 5%
SDS-polyacrylamide gel and probed for BRCA1 expression
(216 kDa). Loading accuracy was measured by Amido black
staining. Figure is representative of at least 3 independent tri-
als.
BRCA1
MCF 7    MCC5   H103261-77
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Figure 2
Reduced HIO3261-77 cell viability after 1 µM STS treatment. A) Triplicate samples of cells were treated with 1 µM STS for 3 h
and assayed for cell growth by MTS at 0, 24, and 48 h. Results shown were percent growth of untreated cells. B) Triplicate
samples of untreated cultures were grown in the absence of STS and results were shown as the linear regression of BRCA1wt
and BRCA1+ cells. Both figures were generated from samples counted in triplicate. C) Trypan blue analysis was performed on
STS-treated cultures to assay for cell death at 0, 1, 3, 24, and 48 h. Both adherent and suspended cell cultures were counted,
and the results were reported as the percent of dead cells from the combined counts. Error bars and p values were generated
from 3 independent treatments for each cell line.
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assay at 0, 24, and 48 h (Figure 2A). Results were reported
as percent growth of respective untreated cells allowed to
grow in serum containing media. BRCA1wt cells grew
17% greater at 24 h and 8% greater at 48 h than BRCA1+
cells. This difference proved to be statistically significant
(p < .03 and p < .01, respectively). BRCA1wt cells ap-
peared to recover at 72 h while BRCA1+ cells continued to
decline in growth (data not shown).
To confirm that the difference in cell viability was due to
alterations in survival response after STS treatment and
not an intrinsic property of the individual cell lines,
growth of both cell lines was examined by MTS assay un-
der the same conditions in the absence of STS (Figure 2B).
Linear regression analysis of cell growth revealed that the
slopes of the BRCA1wt cells, (0.12) and that of the
BRCA1+ cells, (0.14) were essentially the same.
To ensure the survival difference after STS treatment seen
between the BRCA1wt and BRCA1+ cells was associated
with cell death, a trypan blue exclusion assay was conduct-
ed (Figure 2C). Cells were plated in triplicate and both ad-
herent and suspended cell populations were assayed with
results reported as percent of total population dead. No
appreciable difference was observed in the amount of
death between the cell lines at 0, 1, or 3 h (1%, 3.5%, and
2.5%, respectively). There was, however, a significantly
higher percentage of dead cells in the BRCA1+ cell line at
24 h (12.8%; p < .027) and 48 h (24.6%; p < .001).
Amino-terminal BRCA1 mutation was associated with ele-
vated caspase 3 activation following STS treatment
To investigate the role of amino-terminal of BRCA1 in ap-
optosis, the effect of STS was examined on elements of the
caspase pathway (Figure 3). First, to determine whether a
mutation in amino-terminal RING domain of BRCA1
preferentially targeted either the mitochondrial [25] or
Fas/Fas ligand apoptotic pathway [24], levels of the re-
spective initiator caspases 9 and 8 were determined. Both
cell lines produced activated caspases 8 and 9 by 1 h after
treatment with equivalent levels at 3 h.
Next, levels of the executioner caspase 3 were examined.
Once more, both cell lines produced activated caspase 3
by 1 h after treatment. However, BRCA1+ cells showed
significantly more active caspase 3 by 3 h after treatment
than the wild type. To quantify the difference in caspase
activation, the immunoblots were scanned and analyzed
via ImagQuant densitometry (Table 1). Densitometric
analysis revealed that although BRCA1+ cells initially had
lower levels of caspase 3, after 3 h STS treatment, caspase
3 levels were 72% higher. Levels of STS-induced caspase 7,
a structural and functional homolog of caspase 3 [32]
were also evaluated (Figure 3). Procaspase 7 began to be
cleaved at 1 h of treatment and was completely processed
by 3 h of treatment in both BRCA1 wt and BRCA1+ cells.
Although caspase 7 plays a subsidiary role in DNA frag-
mentation and apoptosis morphology [33], densitometric
analysis illustrated that BRCA1+ cells contained substan-
tially reduced levels of procaspase 7 in untreated cells
(39% of that seen in BRCA1wt), and during initial STS
treatment (31% of that seen in BRCA1wt at 0.5 h).
To determine whether elevated levels of cleaved caspase 3
resulted in increased cleavage of caspase 3 substrates,
DFF45 cleavage was studied (Figure 3). Degradation of
full length DFF45 was used to indicate caspase 3 activity.
In both cell lines, DFF45 began to significantly degrade by
1 h after treatment. In BRCA1wt cells, the levels of full
length DFF45 were 95% of control at 0.5 h, 40% of con-
trol at 1 h, and 22% of control at 1.5 h. In contrast, in
BRCA1+ cells, full length DFF45 was only 71% of control
at 0.5 h, 16% of control at 1 h, and 10% of control at 1.5
h (Table 1).
Amino-terminal BRCA1 mutation caused increased degra-
dation of caspase-linked DNA repair proteins
To ascertain whether increased caspase 3 activity in
BRCA1+ cells could also affect DNA repair pathways, the
DNA repair enzymes PARP, a known substrate of caspase
Figure 3
Effect of amino-terminal BRCA1 mutation in caspase-
dependent apoptosis. BRCA1wt and BRCA1+ cells were
treated with 1 µM STS and adherent populations were col-
lected at 0, .5, 1, 1.5, and 3 h. Cells were lysed and separated
via 12.5% SDS-PAGE for western immunoblot analysis. Mem-
branes were probed with antibodies for activated caspase 9
(37 kDa), caspase 8 (43 kDa), caspase 3 (19 kDa), procaspase
7 (36 kDa), and full length DFF45 (45 kDa). Membranes were
then reprobed with anti-actin to ensure proper loading
(shown immediately under respective caspases). Membranes
are representative of at least 3 independent treatments.
procaspase 7
cleaved caspas
cleaved caspas
actin
BRCA1wt BRCA1+
C. 511 . 5 3 C . 5 11 . 5 3
actin
actin
procaspase 8
cleaved caspas
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3, [27] and ERCC1, a repair protein not dependent on cas-
pase 3 [35] were examined (Figure 4). Interestingly, cleav-
age and inactivation of PARP was noted only at 3 h after
STS treatment in BRCA1wt cells. In contrast, accelerated
cleavage and inactivation of PARP was seen in BRCA1+
cells as early as 1 h after STS treatment. Levels of ERCC1
were not significantly different between BRCA1wt and
BRCA1+ cells.
Discussion
A frameshift mutation in the amino-terminal of the
BRCA1 gene disrupts the RING domain and all domains
after it. Our data showed that a BRCA1 mutation inter-
rupting the RING domain altered apoptosis in ovarian
surface epithelial cells. While there was no difference in
overall growth between BRCA1+ and BRCA1wt cells,
BRCA1+ cells showed a marked reduction in survival fol-
lowing STS treatment. Reduced cellular survival in
BRCA1+ cells was associated with increased cell death due
to alterations in apoptosis. No difference was detected in
the levels of caspase 9 or caspase 8 among the BRCA1+ or
BRCA1wt cells, suggesting that the reduced cell survival in
BRCA1+ cells was not associated with a difference in initi-
ation of either the mitochondrial or the Fas/FasL apoptot-
ic pathways. In contrast, STS induced 72% greater caspase
3 activity in BRCA1+ compared to BRCA1wt cells. The en-
hanced caspase 3 activity in BRCA1+ cells was clearly func-
tional and resulted in increased proteolysis of
downstream targets of caspase 3. That is, we found 40%
less full length DFF45 at 1 h and 42% less at 1.5 h in
BRCA1+ cells compared with BRCA1wt cells. The cleavage
and subsequent deactivation of this caspase 3-dependent
DNase inhibitor suggested that amino-terminal BRCA1
mutations enhance cellular apoptosis contributing to
poor cell survival.
With BRCA1's extensive connection to DNA repair already
established [35], we also examined whether an amino-ter-
minal BRCA1 mutation reduced cellular survival by en-
hanced caspase 3-dependent cleavage and subsequent
inactivation of the caspase 3-dependent DNA repair en-
zyme PARP. As with DFF45, PARP cleavage was signifi-
cantly enhanced in BRCA1+ cells suggesting that
decreased DNA repair capacity in BRCA1+ cells may, in
part, be due to premature inactivation of PARP. This pat-
tern was not seen with ERCC1 and may be due to the
choice of apoptotic stimulus used. While the exact mech-
anism remains unclear, STS has been shown to initiate
caspase driven apoptosis in a manner distinct from chem-
otherapeutic agents such as cisplatinum, etoposide, and
tamoxifen, which directly cause DNA damage and tend to
favor ERCC1 activation [37,38].
Previous studies have shown that truncation of the highly
acidic carboxy-region BRCT resulted in resistance to cas-
pase induced apoptosis [17]. Further, this failure of apop-
tosis was traced specifically to caspase 8 and the Fas/FasL
pathway. In contrast, our data showed that the 185delAG
mutation, affecting the amino-terminal domain of
BRCA1, conferred an increased apoptotic response with
no caspase pathway preferentially selected. Instead, this
amino-terminal mutation favored elevated caspase 3 lev-
els that subsequently facilitated enhanced apoptosis by
inactivating the caspase-dependent DNA repair proteins
PARP and by inactivating DFF45, an inhibitor of the cas-
pase-dependent DNase, DFF40. The nature of the
185delAG frameshift makes it difficult to determine if the
apoptotic alterations seen are directly caused by the muta-
tion or by downstream effects of it and certainly deserves
further scrutiny. In this way, carboxy- and amino-terminal
BRCA1 mutations may target two distinct anti-apoptotic
pathways. Therefore, disruptions in either or both BRCA1
terminals effect apoptotic response.
Table 1: Densitometric analysis of selected members of the caspase pathway.
BRCA1wt BRCA1+
Caspase 3 Procaspase 7 DFF45 Caspase 3 Procaspase 7 DFF45
Control nd 7.44 21.7 nd 2.9 21.0
0.5 h nd 5.4 20.52 nd 1.66 14.94
1.0 h 1.4 1.68 8.71 0.61 1.04 3.44
1.5 h 2.4 .35 4.86 2.08 .66 2.06
3.0 h 2.63 nd nd 3.64 nd nd
Densitometric analysis of selected members of caspase pathway. Representative immunoblots for activated caspase 3, 
procaspase 7, and full length DFF45 were scanned and analyzed via the ImagQuant software application. Values reported were 
normalized to the immunoblots' respective actin levels. An entry of 'nd' represents a value not detectable by the application.Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/7
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In summary, our findings suggest a possible novel mech-
anism by which the amino-terminal of BRCA1 suppresses
apoptosis and facilitates DNA repair in human ovarian
surface epithelial cells.
Conclusions
The 185delAG mutation in the BRCA1 gene disrupts the
zinc linker region of the amino-terminal RING domain.
Disruption of this domain triggered an elevated caspase 3-
dependent apoptotic response and affected downstream
proteins such as DFF45 and PARP.
Materials and Methods
Cell Culture
SV-40 large T-antigen transfected human ovarian surface
epithelial cell lines, MCC5 and HIO3261-77, were derived
from women with and without a family history of breast/
ovarian cancer, respectively [31]. While MCC5 cells were
derived from a patient denoted as wild type BRCA1 status,
HIO3261-77 cells were derived from a patient character-
ized as 185delAG mutated [39]. Dr. W. Bai (USF) kindly
provided the MCF7 breast cancer carcinoma line. Cells
were maintained in Medium 199/MCDB 105 (1:1) (Sig-
ma, St. Louis, MO) with 5% fetal bovine serum (Gibco-
BRL, Rockville, MD) and 10 ug/ml gentamicin
(GibcoBRL) in 5% CO2/95% air at 37°C as described pre-
viously [31,40].
Induction of Apoptosis and Cell Viability Assessment
Cells were grown in 100 mm tissue culture disks until con-
fluent. Cultures were treated with 1 µM staurosporine
(STS) (Sigma) in serum containing medium until collect-
ed. Control samples were rinsed in DPBS, drained, and
fresh medium was added.
Cell growth was determined by the MTS (Promega, Madi-
son, WI) colorimetric assay following STS treatment. The
assay was performed in 96 well microtiter places accord-
ing to manufacturer's instructions and is based on soluble
formazan production by dehydrogenase enzymes found
in metabolically active cells. Samples were seeded in six
wells per time point at 2.5 ×  103 cells per well. Absorbance
was determined at 490 nm using a Dynex MRX plate read-
er (Dynex Technologies, Chantilly, VA) and the results ex-
pressed as the mean absorbance of triplicate experiments
± SE.
SDS-PAGE and Western Blot Analysis
In order to observe changes at the onset of apoptosis, only
adherent cell populations were trypsinized, pelleted 5
minutes at 500 ×  g, and lysed in ice cold lysis buffer (10
mM Tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM EGTA, 0.1
mM PMSF, 5 mM β -mercaptoethanol, 0.5% CHAPS, 10%
glycerol) for 30 minutes at 4°C. Lysates were then centri-
fuged at 100,000 ×  g for 1 h at 4°C. Protein concentrations
of the lysates were determined using the DC Protein Assay
(Biorad, Hercules, CA) according to the manufacturer's in-
structions. Fifteen micrograms of protein were added to
4X loading buffer (250 mM Tris pH 6.8, 8% SDS, 20%
glycerol, 0.012% bromophenol blue, 4% β -mercaptoeth-
anol), heated to 95°C for 5 minutes, electrophoresed in
12.5% SDS-polyacrylamide gels, and transferred to nitro-
cellulose membrane (Amersham Piscataway, NJ) via
semi-dry transfer. Due to the high molecular weight of
PARP, SDS-PAGE was performed using 7% polyacryla-
mide gels, and proteins were then transferred to PVDF
membrane (Biorad) via wet transfer. All membranes were
blocked for 1 hour with 5% non-fat milk Tris Buffered Sa-
line plus 0.1% Tween-20 (T-TBS) and incubated at least
overnight at 4°C in primary antibody.
Polyclonal antibodies to caspase 3, caspase 9, and PARP
were purchased from Cell Signaling (Beverly, MA), a mon-
oclonal antibody to caspase 7 and a polyclonal antibody
to DFF45 were obtained from BD Transduction (San Di-
ego, CA). Polyclonal anti-caspase 9, and monoclonal ac-
tin antibodies were purchased from Alexis (San Diego,
CA) and Sigma, respectively. Membranes were incubated
and developed according to the Enhanced Chemilumi-
nescent Protocol, according to manufacturer's instruc-
tions (Amersham). After initial blotting, membranes were
reprobed for actin to ensure even loading.
BRCA1 status of the cell lines used in this study was con-
firmed via western immunoblotting. Cells were mixed
with equal volume of 2X loading buffer, vortexed and
boiled for 5 minutes. One hundred thousand cells were
separated by 5% SDS-PAGE, transferred by wet-transfer to
PVDF membrane, and blotted as described above using
monoclonal antibody specific for the N-terminus of
BRCA1 (Oncogene Boston, MA). After blotting, the PVDF
membrane was stained with 2% amido black in 7% gla-
Figure 4
Effect of amino-terminal BRCA1 mutation on DNA repair
protein expression. BRCA1wt and BRCA1+ cells were
treated and lysed as in Figure 3 and probed for cleaved PARP
(86 kDa) and ERCC1 (36 kDa). Membranes were then
probed for actin for loading consistency. Images are repre-
sentative of at least 3 independent treatments blotted twice.
C   .5    1   1.5   3    C   .5    1  1.5   3
PARP
actin
ERCC1
actin
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cial acetic acid and the protein fronts of all lanes were
compared for loading accuracy.
Statistical Analysis
Samples for MTS and trypan blue exclusion assays were
performed in triplicate and the data subjected to the Stu-
dent's paired t-test analysis for determination of statistical
significance between BRCA1+ and BRCA1wt samples.
Two-tailed results are reported as P values within the cor-
responding figures.
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